Peptide Brand Transparency Checklist: Documented Attributes That Separate Verifiable Sellers from the Rest

Why a Transparency Checklist Matters for Peptide Brands

The U.S. peptide research chemical market operates largely outside the prescription drug supply chain. Most peptides sold by domestic vendors are classified as research chemicals, meaning they are not FDA-approved for human use and are not subject to the same manufacturing oversight that governs pharmaceutical products. That regulatory gap makes independent verification of brand claims the primary tool available to buyers.

A transparency checklist is not a quality guarantee. It is a documentation audit. The goal is to record what a brand has disclosed publicly and what can be independently confirmed, then note what is absent. A brand that publishes a COA, names its principals, and lists a physical address has created a verifiable record. A brand that does none of those things has not, regardless of how its marketing reads.

This registry applies the same four-category framework to every brand it profiles: ownership transparency, testing disclosure, labeling compliance, and contactability. Each category has specific, documentable sub-criteria listed in the sections below.

Category 1: Ownership Transparency

Ownership transparency refers to whether the legal entity behind a brand is publicly identifiable. The minimum standard is a registered business name that appears in a state or federal database. Stronger disclosure includes named principals or officers, a year of founding, and any relevant professional affiliations or licenses.

Brands that operate under a trade name without a traceable registered entity present a verification gap. A buyer cannot confirm jurisdiction, cannot file a complaint with a state attorney general, and cannot cross-reference the operator against any professional licensing board. This is a factual gap in the record, not a moral judgment.

When this registry profiles a brand, it checks state business registries, the Better Business Bureau database, and any DUNS or SAM.gov records where applicable. Brands that appear in at least one of those sources receive a notation. Brands that do not are listed as unverified on this attribute.

Category 2: Testing Disclosure

Testing disclosure covers whether a brand publishes certificates of analysis (COAs) from third-party laboratories, and whether those COAs contain enough information to be independently verified. A COA that names the testing laboratory, lists the lot number, shows the test date, and reports both identity confirmation and purity percentage meets the baseline standard. A COA that omits the lab name or shows no lot-specific data does not.

The testing methods matter as well. High-performance liquid chromatography (HPLC) is the standard method for purity quantification in peptide research chemicals. Mass spectrometry (MS) confirms molecular identity. Brands that disclose which methods were used, and whose COAs show chromatograms or spectral data, provide a more complete record than those that publish only a summary percentage.

This registry also notes whether COAs are lot-specific or generic. A single COA applied to all batches of a product is a weaker disclosure than a COA tied to a specific production lot with a traceable number. Lot-specific COAs allow a buyer to match the document to the product they received, which is the point of the exercise.

Independent verification is possible when the testing lab is named. Buyers can contact the lab directly to confirm the COA is authentic. Brands whose COAs name accredited labs, such as those holding ISO/IEC 17025 accreditation, provide a higher level of verifiability than those using unnamed or unaccredited facilities.

Category 3: Labeling Compliance

Labeling compliance refers to whether a brand's product labels accurately reflect the compound inside the vial, the stated quantity, and the appropriate research-use designation. For research chemicals sold in the United States, labels should not carry disease-treatment claims, should not imply FDA approval, and should not include human-use directions of any kind.

The compound name on the label should match the COA. If a vial is labeled as BPC-157 at 5 mg, the COA should confirm the identity as BPC-157 and the purity and quantity should be consistent with that claim. Discrepancies between label claims and COA results are a documented red flag in this registry.

Labels that include the phrase 'for research use only' or an equivalent disclaimer are consistent with the regulatory status of research chemicals. Labels that omit this designation, or that include language suggesting the product is intended for human consumption, represent a compliance concern that this registry records as a notation against the brand.

This registry cross-references label claims against available COA data for every brand profile. Where a brand does not publish COAs or where label claims cannot be matched to a verifiable document, that gap is recorded in the profile.

Category 4: Contactability and Business Accountability

Contactability is the most basic accountability standard. A brand should have a working email address, a customer service channel that responds within a reasonable window, and a physical or registered mailing address that can be independently confirmed. Brands that list only a contact form with no named entity behind it score lower on this criterion than those with a named business address.

Phone numbers, when listed, can be cross-referenced against business registries. A phone number that matches the registered business address adds to the verifiable record. A number that connects to an unrelated entity or goes unanswered is noted as a discrepancy.

Return and dispute policies are also part of contactability in this registry's framework. A brand that publishes a clear, written policy for product disputes has created a documented accountability mechanism. A brand with no published policy has not, and that absence is recorded.

This registry attempts direct contact with every brand it profiles, using the contact information listed on the brand's own website. Response time and the completeness of the response are both recorded. Brands that do not respond to a documented inquiry within 14 days are listed as non-responsive on this attribute.

How This Registry Uses the Checklist

Each brand profile on this registry is built from the four categories above. The profile records what was found, what was absent, and what could be independently verified at the time of review. Profiles are dated so readers know when the information was current.

This registry does not score or rank brands on a numerical scale. The checklist is a documentation tool, not a rating system. A brand that meets all four criteria is described as fully documented on these attributes. A brand that meets none is described as unverified across all four. The distinction is factual, not evaluative.

Readers should treat every profile as a snapshot. Brand practices change. A COA that was published in one quarter may be removed or updated in the next. This registry notes the review date on every profile and encourages readers to verify current documentation directly with the brand before drawing conclusions.

Summary: The Four Documented Attributes

The checklist used by this registry covers ownership transparency, testing disclosure, labeling compliance, and contactability. Each attribute has a binary outcome in the profile: documented or not documented, with notes on what was found.

No single attribute is sufficient on its own. A brand with excellent COAs but no traceable registered entity still has a gap in the ownership record. A brand with a named owner but no third-party testing has a gap in the testing record. The checklist is designed to surface all four gaps simultaneously so readers have a complete picture.

• Ownership transparency: registered business entity traceable in a public database
• Testing disclosure: lot-specific COA from a named third-party lab using HPLC or MS
• Labeling compliance: compound name matches COA, research-use designation present, no human-use language
• Contactability: working contact channel, physical or registered address, published dispute policy